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Seroepidemiological study on the spread of SARS-CoV-2 in 
Germany: Study protocol of the ‘CORONA-MONITORING 
bundesweit’ study (RKI-SOEP study) 
Abstract
The SARS-CoV-2 coronavirus has spread rapidly across Germany. Infections are likely to be under-recorded in the 
notification data from local health authorities on laboratory-confirmed cases since SARS-CoV-2 infections can proceed 
with few symptoms and then often remain undetected. Seroepidemiological studies allow the estimation of the proportion 
in the population that has been infected with SARS-CoV-2 (seroprevalence) as well as the extent of undetected infections. 
The ‘CORONA-MONITORING bundesweit’ study (RKI-SOEP study) collects biospecimens and interview data in a 
nationwide population sample drawn from the German Socio-Economic Panel (SOEP). 
Participants are sent materials to self-collect a dry blood sample of capillary blood from their finger and a swab sample 
from their mouth and nose, as well as a questionnaire. The samples returned are tested for SARS-CoV-2 IgG antibodies 
and SARS-CoV-2 RNA to identify past or present infections. 
The methods applied enable the identification of SARS-CoV-2 infections, including those that previously went undetected. 
In addition, by linking the data collected with available SOEP data, the study has the potential to investigate social and 
health-related differences in infection status. Thus, the study contributes to an improved understanding of the extent of 
the epidemic in Germany, as well as identification of target groups for infection protection. 
  SARS-COV-2 · COVID-19 · SEROEPIDEMIOLOGICAL STUDY · CROSS-SECTIONAL STUDY · STUDY PROTOCOL 
1. Introduction
The novel coronavirus SARS-CoV-2 (Severe Acute Respira-
tory Syndrome Coronavirus 2), which was first identified in 
the Chinese city of Wuhan in December 2019, has rapidly 
spread across the globe. The first cases of COVID-19, the 
disease caused by the virus, were reported in Germany at 
the end of January 2020 [1, 2]. Shortly thereafter, the virus 
had spread across Germany, so that by the beginning of 
March 2020, cases of COVID-19 had been recorded in all 
16 federal states [3]. 
To contain the further spread of the virus, regulations on 
social distancing and movement outside of the home, 
severe restrictions on businesses as well as closures of 
childcare centres and schools have been imposed across 
Germany since mid-March 2020. After a peak of newly noti-
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detection of SARS-CoV-2 antibodies, on the other hand, 
enable the identification of past infections, including those 
that previously went undetected. For this reason, the World 
Health Organization recommends such seroepidemiolog-
ical studies to improve the understanding of the spread of 
the virus in the population [7].
In spring 2020, the RKI thus began planning various 
serological studies to determine the proportion of the pop-
ulation with antibodies (seroprevalence) against the novel 
coronavirus. Serological testing of blood donations for 
SARS-CoV-2 antibodies (SeBluCo study), which the RKI is 
conducting in cooperation with blood donation services 
and virology institutes in 28 regions, began in April [8]. In 
May, data collection began for the ‘CORONA-MONITORING 
lokal’ study, in which the RKI has been testing population 
samples for SARS-CoV-2 antibodies as well as for current 
viral infection in four areas especially affected by the 
COVID-19 pandemic [9]. In addition, a study is being con-
ducted in conjunction with the German Youth Institute to 
coincide with childcare centres being re-opened, which 
should provide insight into the role of preschool children 
in transmitting the disease [10]. The ‘CORONA-MONITO- 
RING bundesweit’ study (RKI-SOEP study) presented here 
focuses on the general population of Germany and has 
been developed by the RKI together with the German Insti-
tute for Economic Research (DIW). In this study, the 
research-based infrastructure of the German Socio-Eco-
nomic Panel (SOEP) at the DIW is used to examine past 
and current infections with SARS-CoV-2 in people from all 
over Germany. It involves an analysis of IgG (immunoglob-
ulin G) antibodies from self-collected capillary blood sam-
ples and viral RNA (ribonucleic acid) from oral-nasal swabs. 
fied daily COVID-19 cases in March, infection numbers 
decreased considerably over the following weeks, enabling 
a gradual relaxation of containment measures from the end 
of April. The number of SARS-CoV-2 infections in Germany 
in the summer months was comparatively low [4]. From the 
end of September onwards, however, the number of cases 
significantly increased, with the total number of cases noti-
fied in Germany more than doubling between mid-August 
and the end of October [5, 6]. A total of 518,753 SARS-CoV-2 
infections and cases of COVID-19 had been confirmed by 
laboratory diagnosis in Germany by 31 October 2020, cor-
responding to a cumulative incidence of 624 cases per 
100,000 people [6]. New measures to contain the pandemic 
were subsequently introduced at the beginning of Novem-
ber 2020. People were asked to reduce their contact with 
those from other households to an absolute minimum. 
Meetings in public were severely restricted, and large parts 
of the hospitality industry, as well as leisure, sports and cul-
tural facilities, were closed. Tourist accommodation and 
events for entertainment purposes were banned, although 
schools, childcare centres and shops initially remained open.
The figures and findings on the development of SARS-
CoV-2 in Germany mentioned above are based on the stat-
utory reporting of laboratory-confirmed cases of infection 
to health authorities. These data are collected nationwide 
according to the Protection against Infection Act (Infekti-
onsschutzgesetz, IfSG) and compiled by the Robert Koch 
Institute (RKI). Since SARS-CoV-2 infections often remain 
undetected, for example, if a case remains unnoticed 
because of a lack of symptoms, it must be assumed that 
the incidence of infection is underrepresented in IfSG noti-
fication data. Population-based studies with serological 
Seroepidemiological studies 
can contribute to an 
improved understanding  
of virus spread within the  
population.
Journal of Health Monitoring 2021 6(S1)
Seroepidemiological study on the spread of SARS-CoV-2 in Germany (RKI-SOEP study)Journal of Health Monitoring
4
CONCEPTS & METHODS
non-pharmaceutical interventions to contain the COVID-19 
pandemic and to develop targeted vaccination strategies.
 
2. Methodology
2.1 Study design and sampling
Study design 
The ‘CORONA-MONITORING bundesweit’ study (RKI-
SOEP study) is a population-based seroepidemiological 
observational study based on the DIW’s nationwide SOEP 
population samples. The SOEP is a longitudinal survey in 
Germany of private households and all persons living in 
them that has been conducted annually since 1984 [11]. The 
survey covers a wide range of topics, from demographics, 
income, the labour market, education and health through 
to people’s basic orientations, concerns and levels of 
satisfaction. 
Sampling
The SOEP comprises a total of 25 different sub-samples 
made up of random samples of all private households in 
Germany, as well as samples from specific population 
groups such as migrants, refugees, families, high-income 
earners, households in socially disadvantaged neighbour-
hoods, homosexual and bisexual people, etc. [11]. The exact 
composition of samples, willingness to participate, drop-
out mechanisms and consequent changes to SOEP sam-
ples since the initial SOEP survey in 1984 are described in 
detail elsewhere [13]. Among SOEP participants, the will-
ingness to participate in the SOEP again is generally high, 
at about 85%. Nevertheless, like all comparable survey 
studies of the general population, the SOEP does record 
The SOEP is a multidisciplinary, long-term study that 
involves interviews of around 30,000 people from about 
18,000 households throughout Germany every year [11]. An 
important aspect of this study is that the same people are 
interviewed every year. As a result, existing SOEP infrastruc-
ture can be used alongside a range of information on SOEP 
participants from previous survey waves, for example, infor-
mation on living conditions, social situation and state of 
health, which can provide crucial information on the spread 
of SARS-CoV-2 in different population subgroups, and 
potentially reveal mechanisms involved in the spread of 
the virus [12]. 
The objectives of the ‘CORONA-MONITORING bundes-
weit’ study (RKI-SOEP study) are to analyse the following 
within a Germany-wide sample of the general adult popu-
lation:
1. the seroprevalence, i.e., the proportion of the popula-
tion in Germany with detectable IgG antibodies against 
SARS-CoV-2, differentiated by age group and sex,
2. the extent of undetected SARS-CoV-2 infections,
3. risk and protective factors for a SARS-CoV-2 infection, 
taking demographic, socioeconomic and health-related 
factors into account.
In addition, the RKI-SOEP study aims to lay the foun-
dations for an analysis of the long-term effects of infection 
with SARS-CoV-2 over the course of people’s lives. More-
over, it can serve as a starting point for a Germany-wide 
analysis of developments over time in the spread of anti-
bodies against SARS-CoV-2 at population level. The results 
of the study should also help to support the planning of 
The RKI-SOEP study  
uses the infrastructure 
provided by the German 
Socio-Economic Panel 
(SOEP) to test people 
throughout Germany for  
past and present  
SARS-CoV-2 infections.
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Recruitment of participants and field control 
All SOEP households from the gross sample receive a let-
ter inviting them to participate in the study. The fieldwork 
is carried out by the field study institute Kantar GmbH 
based in Munich. Initially, all target households are sent 
a letter informing them that they will receive an invitation 
to participate in the study in the next few days. This letter 
includes a leaflet with information about the study and a 
letter from the German Federal Minister of Health encour-
aging participation. A few days later, each target person 
receives a letter inviting them to participate in the study. 
Target persons are defined as SOEP participants who were 
at least 18 years old as of 1 September 2020, who partic-
ipated in the SOEP surveys in 2019 and/or 2020 and who 
have not explicitly stated that they do not wish to partic-
ipate in future studies. These invitations contain both a 
personal invitation and study materials in German (data 
privacy statement, consent form, participation plan, short 
questionnaire, two specimen collection sets for self- 
sampling including instructions and packaging for post-
ing the samples safely as well as two return envelopes: 
one for the consent form and short questionnaire, and 
one for the collected samples). As an incentive to partic-
ipate in the study, potential participants are told that they 
will receive the laboratory results from the samples they 
collect, meaning that via the study they will find out their 
antibody and infection status. Participants who do not 
answer this letter receive a written reminder to participate 
in the study around two to three weeks after receiving the 
invitation. 
selective panel attrition due to people’s refusal to partici-
pate again. SOEP compensates for panel attrition with 
regular refreshment samples and by making methodolog-
ically high-quality weighting factors available for popula-
tion-related analyses (see also [13]). 
The ‘CORONA-MONITORING bundesweit’ study (RKI-
SOEP study) includes the SOEP core samples [14], the 
innovation sample [15] and the new migration samples 
(M1 and M2 [16, 17]). This renders a gross sample of a total 
of 31,675 persons aged 18 to 101 years from 19,574 house-
holds. This gross sample covers all 401 districts in Ger-
many. There are districts with between one and 540 SOEP 
households. On average, the SOEP samples contacted for 
participating in the study contain 49 households per dis-
trict with a standard deviation of 54 households. One SOEP 
household thereby includes between one and 12 persons, 
with an average of 1.6 persons aged 18 and over with a 
standard deviation of 0.7.
Inclusion and exclusion criteria
People are included who 
  live in a SOEP household from one of the core samples, 
the innovation sample or the migration samples 
(M1 and M2) 
  are at least 18 years old
  provide written consent to participate in the study
  are able to take a capillary blood sample and an oral- 
nasal swab themselves (self-sampling).
People who lack the necessary German language skills 
to understand the German-language study material cannot 
successfully participate in the study.
Journal of Health Monitoring 2021 6(S1)
Seroepidemiological study on the spread of SARS-CoV-2 in Germany (RKI-SOEP study)Journal of Health Monitoring
6
CONCEPTS & METHODS
the field phase due to the greater administrative effort 
involved in using the M1 and M2 samples.
Data collection
The study consists of two parts: an examination and an 
interview. In the examination, participants take their own 
biological samples for a laboratory analysis of SARS-CoV-2 
virus material. This determines their SARS-CoV-2 antibody 
status by means of ELISA (enzyme-linked immunosorbent 
assay), as well as current infection status by means of PCR 
(polymerase chain reaction; see also Chapter 2.3). In the 
interview, a short questionnaire is used to collect supple-
mentary data on the participants. 
Participants are asked to provide a dry capillary blood 
sample from their fingertip for laboratory analysis of their 
antibody status. This can detect a previous infection with 
SARS-CoV-2. To test for a current infection with SARS-CoV-2, 
the participants are asked to provide a swab sample from 
their mouth and nose. Specimens are collected by the par-
ticipants themselves (Figure 1) using CE-certified Euroim-
mun sample collection and submission kits (blood sample) 
and Copan eSwab collection systems (swab) sent by post. 
The blood sampling set contains detailed illustrated instruc-
tions with written explanations under each picture, a blood 
collection card, a compress, two plasters, two alcohol 
swabs, two sterile lancets and a sealable plastic bag con-
taining a desiccant. There are five circles on the blood col-
lection card to mark where blood should be collected. The 
collection and transport items supplied for the oral-nasal 
swab include a sample tube, a swab, a transport tube and 
a protective bag with an absorbent insert. The illustrated 
instructions in the specimen collection kit also include a 
The field phase started when the initial information let-
ters were sent to target households on 30 September 2020. 
The first invitations including study materials were sent to 
each target person in the target households from 2 October 
2020 onwards, the data collection phase therefore started 
at the beginning of October 2020 and is expected to 
continue until February 2021. 
Due to the logistics of sampling, people in the gross 
sample were divided into four groups, which were invited 
to participate in the study one after the other. When cre-
ating the first three groups, stratification by federal states 
took into account that the measures taken to contain the 
spread of SARS-CoV-2 infections differed in part between 
federal states. In order to depict infection rates sufficiently 
accurately within the individual groups, households in 
the sample were also stratified in each federal state 
according to the reported cumulative incidence of infec-
tion at the district level (as of 14 September 2020). For 
this purpose, households in the RKI-SOEP gross sample 
in each federal state were assigned to one of three inci-
dence categories based on the cumulative incidence per 
100,000 inhabitants. Assignment to the low, medium or 
high incidence categories was based on terciles. From 
each of these three groups, households in the RKI-SOEP 
gross sample, minus the more recent SOEP migrant sam-
ples (M1 and M2), were randomly assigned to the first 
three groups in a ratio of 50%/25%/25%. The first group 
thus includes 14,535 adults and the two following groups 
7,181 and 7,078 adults. The fourth group consists of peo-
ple from the more recent SOEP migrant samples 
(M1 and M2) and comprises 2,881 adults. This fourth 
group was not stratified and was only used at the end of 
Participants are asked to 
return a dry blood sample,  
an oral-nasal swab and a 
questionnaire.
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attach machine-readable barcodes to the blood collection 
cards, swab tubes, questionnaires and consent forms. 
These barcodes are included in the package in the form of 
adhesive labels. The questionnaires and consent forms, 
which must also have barcodes attached, are returned to 
Kantar together.
Communication of results
If the laboratory results do not require extra contact with 
study participants and are not subject to legal notification 
obligations, they are sent to participants in the form of 
individual result reports. For participants with questions 
about the results, there is the study-specific website with 
web link and a QR code for access to supporting video 
instructions. In addition, there is a website specific to the 
study which has a list of frequently asked questions and 
answers (FAQ list). Study subjects are advised not to col-
lect samples if there are any impediments or acute health 
conditions that would interfere with taking a sample or 
make it painful to do so. 
Participants then send the collected biospecimens to 
the RKI in the appropriate enclosed envelope. Participants 
are requested to send specimens on the day of collection 
if at all possible. In order to assign test results to the per-
sonal data, which is stored at the Kantar field institute, and 
to link these results to the interview data, participants 
(a) Dry blood sample
(b) Oral-nasal swab
Figure 1 
Self-collection of capillary blood from the 
fingertip (a) and a swab from the 
mouth and nose (b) 
Source: Own diagram
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relevant processes and corresponding quality assurance 
measures (e.g. in the RKI’s internal data management and 
laboratories). Internal reports are prepared and their results 
(i.e. observations and, if applicable, recommendations for 
action) are communicated to the study management at the 
RKI. These reports provide evidence of continued quality 
assurance.
2.3 Methods and survey contents 
Laboratory analytics 
In the examination part of the study, the collected dry blood 
specimens and mouth and nose swab samples are anal-
ysed in the laboratories at the RKI. The dry blood samples 
are punched out of the blood collection card and extracted 
before analysis. To determine the presence of IgG antibod-
ies against the novel coronavirus, Euroimmun’s commer-
cial laboratory test ‘Anti-SARS-CoV-2 ELISA (IgG)’ is used. 
With a sensitivity of 88.3% and a specificity of 99.4% 
(according to a validation study by the Paul Ehrlich Insti-
tute on reference sera, based on the analyses of 676 
pre-pandemic samples and 222 convalescent COVID-19 
patients, the vast majority (96%) of which were obtained 
at least 21 days after the onset of symptoms (personal com-
munication from H. Scheiblauer, 25 September 2020)), the 
test is of high quality and has low cross-reactivity (Info box). 
The analyses are carried out in an automated process using 
Euroimmun’s high-throughput analyser ‘EUROLab Work-
station ELISA’. According to the manufacturer, the dried 
blood samples are stable for 14 days at room temperature, 
and there is very high agreement between the dried blood 
and serum IgG measurement results (ratio: correlation 
FAQ list, a form to contact the medical study staff, and a 
telephone hotline.
In case of a positive PCR test, the relevant health author-
ities are notified within 24 hours and given the participant’s 
information. Immediately after notifying the local health 
authorities, the medical study staff send a written message 
to the person concerned with instructions on what to do. 
Whenever possible, the person who has tested positive is 
phoned by the medical study staff. Participants with a bor-
derline SARS-CoV-2 PCR result are contacted in writing by 
the medical study staff within 72 hours of the result and 
are advised to repeat the PCR test at their local health 
authority. In addition, the medical study staff contact the 
responsible health authority by telephone and in writing.
Quality assurance
Quality assurance measures are integral to the entire study 
process and are implemented by all project partners (Kantar, 
RKI and the SOEP at the DIW). Field monitoring during 
the study and a weekly exchange with all project partners 
make it possible to react quickly to unexpected develop-
ments and take appropriate countermeasures (e.g. field 
time extensions to increase the response rate). Results 
from project meetings are recorded in writing and made 
available to the entire study staff. In addition, extensive 
controls of data quality are carried out. The focus here is 
also on ensuring the protection of study participant data. 
At the RKI, a team from the internal quality assurance 
department 2 has been observing the study and quality 
assurance processes on a random basis. Among other 
measures, they examine the RKI study documents and con-
duct guideline-based interviews with senior RKI staff on 
Info box:  
Sensitivity and Specificity 
Sensitivity indicates the probability with 
which a test correctly identifies people with 
antibodies or a current infection. 
Specificity indicates the probability with 
which a test correctly identifies people who 
do not have antibodies or are currently not 
infected.
The samples are tested for 
SARS-CoV-2 IgG antibodies 
and SARS-CoV-2 RNA  
to identify past and  
present infections.
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participants. A one-page paper questionnaire is filled out 
by each adult person in the household. The questionnaire 
asks questions about previous throat swab tests for SARS-
CoV-2 and the results of these, the reasons for previous 
tests, the duration of any symptoms, and, if applicable, the 
course of a previous known SARS-CoV-2 infection and 
current symptoms.
The data obtained in the ‘CORONA-MONITORING bun-
desweit’ study (RKI-SOEP study) can also be linked to the 
data collected from participants in the regular survey waves 
of the SOEP, for example from the current year or previous 
years. In this way, demographic variables (e.g. age, house-
hold composition, region of residence), socioeconomic 
variables (e.g. education, occupation, income) as well as 
health-related variables (e.g. self-rated general health, 
chronic diseases, smoking, mental health) can be used in 
the RKI-SOEP study to analyse relevant risk and protective 
factors for a SARS-CoV-2 infection.
3. Expected results 
Statistical methods and estimation of sample size 
On the basis of preliminary observations from group one 
in the gross sample, a 50% response rate is assumed for 
the entire sample by the end of the field period. This would 
correspond to a net sample size of about 15,837 adults. 
Assuming that 6% of biospecimens cannot be evaluated 
(an estimate based on empirical data from the first sam-
ples received), this gives a final net sample size of about 
14,890 specimens for analysis. 
The RKI-SOEP sample emerged from a complex study 
design. It is based (for the SOEP core samples) on house-
coefficient 0.981; stability index 0.961. Positive versus 
non-positive result: sensitivity 100%; specificity 98.7% 
regarding serum results; n=215). A separate validation 
study on the agreement between serum and dry blood test 
results will be completed shortly.
Two different in-house PCR tests are performed in par-
allel on swab samples to detect the SARS-CoV-2 genome. 
Test 1 detects the E gene, adapted according to Corman 
et al. [18] and checks for possible errors in RNA extraction 
as well as possible PCR inhibition with a second PCR test 
conducted in parallel. Test 2 is specifically for SARS-CoV-2, 
targeting the ORF1ab region of the viral genome, and can 
detect both the SARS-CoV-2 genome and cellular nucleic 
acids simultaneously, thus indicating successful sampling. 
If both individual tests are positive, the test as a whole is 
considered positive. In a methodology study, the two SARS-
CoV-2 tests showed a very low detection limit; and, accord-
ing to Corman et al [18], the specificity can be up to 100% 
at the laboratory analytical level. However, the relatively 
short time window in which viral material is detectable in 
the oral-nasal cavities of people infected with the virus, 
together with possible handling problems during sampling, 
mean that the actual sensitivity of the test is lower. A vali-
dation study with 103 self-swabs from adults and children 
showed a good level of acceptance and feasibility in regards 
to specimen collection. PCR test results for respiratory 
viruses compared well with the results from professionally 
collected swab specimens [19].
Survey data 
The interview part of the RKI-SOEP study complements the 
laboratory analyses with a short interview of the study 
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It is standard SOEP practice to use a variety of sociode-
mographic characteristics to derive the sample weights (see 
[13] for a detailed overview). In addition, the analyses of non-re-
sponse in the present study consider the effect of the regional 
cumulative incidence of notified SARS-CoV-2 infections on 
people’s willingness to participate. Lastly, the study data are 
weighted by age, sex, as well as social and regional character-
istics to match the German official population statistics (as 
of 31 December 2019) and the 2019 German Microcensus. 
Weighted population estimates such as proportions of 
the population are used to estimate prevalence rates with 
regard to geographical area (federal state level, districts 
and urban districts). Survey procedures from established 
statistical programmes (SAS, Stata or R) are used, whereby 
the correlation within households as well as within munic-
ipalities is taken into account. Alternatively, confidence 
intervals are calculated using a clustered bootstrapping 
procedure at the 95% level.
Estimates are calculated for the following epidemiolog-
ical indicators of infection, among others. The estimates 
are calculated for the total population and stratified by age 
group, sex, characteristics of socioeconomic status and 
other variables collected in the SOEP:
a. Seroprevalence: the proportion of people who test pos-
itive for IgG antibodies (shown with and without adjust-
ment for the sensitivity and specificity of the antibody 
test used)
b. Degree of under-recording: the ratio of the frequency of 
SARS-CoV-2 infections estimated in the RKI-SOEP study 
to notified infections
c. Extent of acute cases newly detected by the PCR test 
(oral-nasal swab).
holds within multiple regional units spread across Germany 
and on the development of these households over the years. 
In addition, willingness to participate differs between the 
various population groups. For example, people with a 
migration background and those in full-time employment 
are less willing to participate than people who do not have 
a migration background or are not in full-time employment 
[20]. The study’s sampling error is therefore higher than if 
it had used a purely random sample, i.e. if individuals were 
drawn from a nationwide list and they all participated. To 
compensate for the resulting deviations from the total pop-
ulation, adjustment factors (sample weights) are calculated 
for the study and used in the analysis. The resulting increase 
in the sampling error can be roughly estimated using the 
so-called design effect [21]. The design effect for SOEP 
weighting factors is 2.8. This means that the expected sam-
ple size of about 15,840 persons corresponds to an effective 
sample size of about 5,320 persons, i.e. with regard to the 
sampling error it is comparable to a purely random sample 
of this size. Table 1 shows the expected case numbers and 
confidence intervals based on the effective sample size for 
different assumed seroprevalence levels in the population.
Table 1 
Expected precision for the seroprevalence 
estimates of infections with SARS-CoV-2 in the 






of the 95% 
confidence interval 
% %
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[28, 29]. In addition, seroepidemiological studies are being 
conducted in the general population of selected regions 
[30] and in a nationwide cohort study of adults [31]. Numer-
ous seroepidemiological studies have also been initiated 
internationally since March and increasingly since April 
2020 [32–36]. Iceland [37], England [38], Brazil [39], Luxem-
bourg [40], the Czech Republic [41] and Spain, among other 
countries, are conducting nationwide studies representa-
tive of their general populations [42]. 
The panel design of the RKI-SOEP study, i.e. that the 
same persons are surveyed every year, as well as the multi-
disciplinary nature of the SOEP survey programme are key 
to the study’s particular potential [12]. On the one hand, 
the panel design means that there is extensive information 
available on the participants from previous SOEP surveys, 
for example on their social situation and living conditions, 
which can be linked to RKI-SOEP study data. This gives the 
study the potential to be used more broadly, for example 
to analyse the social determinants of infection risks. Until 
now there have been hardly any data on the social deter-
minants of infection risk, particularly at the level of individ-
uals [43–45]. The RKI-SOEP study could therefore contrib-
ute to increasing knowledge in this area. On the other hand, 
the panel design also means that prospective data will be 
collected for years to come in the annual follow-ups of RKI-
SOEP study participants within the regular and ongoing 
SOEP survey waves. The SOEP survey regularly includes 
topics such as health, illness, life satisfaction and well- 
being in addition to collecting data on people’s social sit-
uation, demographics and socioeconomic characteristics. 
The data could thus be used to compare social and health- 
related developments over the course of people’s lives 
Statistical associations with background factors (e.g. 
individual or regional characteristics) are assessed using 
weighted measures of association (such as odds ratios, 
average adjusted predictions or attributable risks from 
logistic regression models or Poisson models). 
4. Discussion
The seroepidemiological ‘CORONA-MONITORING bun-
desweit’ study (RKI-SOEP study) combines the serological 
detection of SARS-CoV-2 antibodies in a nationwide sam-
ple of the adult population with PCR tests and interviews. 
This study design enables the identification of both past 
and current SARS-CoV-2 infections, including those that 
previously went undetected, which in turn helps to provide 
a more accurate estimation of the extent of the epidemic 
in Germany. The collected data on the number of people 
who have previously been infected also indicates the extent 
of under-recording of SARS-CoV-2 infections in the nation-
wide IfSG notification data. 
A large number of antibody studies were initiated in 
Germany in 2020 [22, 23]. However, these studies have 
largely been conducted at a local or regional level, or are 
limited to specific settings such as companies, educational 
and healthcare institutions, or to population groups with 
above-average health. About one-third of these studies 
examine the spread of SARS-CoV-2 in the regional general 
population. Several studies have already reported results 
from municipalities that were particularly affected during 
the initial phase of the pandemic (see e.g. [24–27]). Initial 
results are also available from a Munich study as well as a 
study conducted in two urban areas in the city of Bonn 
The study can help provide  
a comprehensive picture of 
the nationwide spread of the 
virus as well as identify risk 
factors and protective factors 
for infection.
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